Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease

Journal of Pineal Research

Volumn 47, Issue 1, 2009, Pages 82-96

  Olcese, James M ^b   Cao, Chuanhai ^a,c,d   Mori, Takashi ^e   Mamcarz, Malgorzata B ^a   Maxwell, Anne ^b   Runfeldt, Melissa J ^a   Wang, Li ^a   Zhang, Chi ^c   Lin, Xiaoyang ^a,c   Zhang, Guixin ^a   Arendash, Gary W ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

amyloid; Alzheimer disease; Cytokines; Melatonin; Memory; Oxidative stress; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; MELATONIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; REFERENCE MEMORY; SPATIAL MEMORY; TASK PERFORMANCE; TRANSGENIC MOUSE; TREATMENT DURATION; WORKING MEMORY;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CATALASE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GLUTATHIONE PEROXIDASE; MAZE LEARNING; MELATONIN; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDOREDUCTASES; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 67649905028     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2009.00692.x     Document Type: Article

References (65)

1. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004 25 : 177 195. (Pubitemid 39642189)
2. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005 9 : 25 39. (Pubitemid 40092916)
3. Wu Y, Feenstra M, Zhou J-N et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003 88 : 5898 5906. (Pubitemid 38033070)
4. Zhou J-N, Liu R-Y, Kamphorst W, Hofman MA, Swaab D. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003 35 : 125 130. (Pubitemid 36960352)
5. Brusco LI, Márquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuro Endocrinol Lett 2000 21 : 39 42. (Pubitemid 30113678)
6. Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res 2007 43 : 404 409. (Pubitemid 47512272)
7. Nilsson LNG, Arendash GW, Leighty RE et al. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging 2004 25 : 1153 1167. (Pubitemid 39094018)
8. Arendash GW, Lewis J, Leighty RE et al. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 2004 1012 : 29 41. (Pubitemid 38648896)
9. Suo Z, Cox AA, Bartelli N et al. GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiol Aging 2007 28 : 1873 1888. (Pubitemid 47539698)
10. Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW. Lifelong immunization with human β-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 2005 130 : 667 684. (Pubitemid 39601440)
11. Arendash GW, Schleif W, Rezai-Zadeh K et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience 2006 142 : 941 952. (Pubitemid 44740473)
12. Arendash GW, Jensen MT, Salem NJ et al. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience 2007 149 : 286 302. (Pubitemid 47576542)
13. Ethell DW, Shippy D, Cao C et al. Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 2006 23 : 351 361. (Pubitemid 44097033)
14. Cracchiolo JR, Mori T, Nazian SJ, Tan J, Potter H, Arendash GW. Enhanced cognitive activity - over and above social or physical activity - is required to protect Alzheimer's mice against cognitive impairment, reduce Aβ deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem 2007 88 : 277 294. (Pubitemid 47321221)
15. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Aβ-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 2009 34 : 63 70.
16. Matsubara E, Bryant-Thomas T, Pacheco Quinto J et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003 85 : 1101 1108. (Pubitemid 36613258)
17. Feng Z, Chang Y, Cheng Y et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004 37 : 129 136. (Pubitemid 39120217)
18. Feng Z, Qin C, Chang Y, Zhang J-T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 2006 40 : 101 109. (Pubitemid 41759407)
19. Pappolla MA, Bozner P, Soto C et al. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 1998 273 : 7185 7188.
20. Poeggeler B, Miravalle L, Zagorski M et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Aβ peptide. Biochemistry 2001 40 : 14995 15001. (Pubitemid 33136121)
21. Skribanek Z, Baláspiri L, Mák M. Interaction between synthetic amyloid-β-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom 2001 36 : 1226 1229. (Pubitemid 33107712)
22. Fraser PE, Nguyen JT, Surewicz WR, Kirschner DA. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J 1991 60 : 1190 1201.
23. Jang M-H, Jung S-B, Lee M-H et al. Melatonin attenuates amyloid β25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci Lett 2005 380 : 26 31. (Pubitemid 40602323)
24. Gunasingh MJ, Philip JE, Ashok BS, Kirubagaron R, Jebaraj WC, Davis CD. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism. Life Sci 2008 83 : 96 102.
25. Tan DX, Reiter RJ, Manchester LC et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002 2 : 181 197.
26. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci 2004 75 : 765 790. (Pubitemid 38737416)
27. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002 2 : 167 179.
28. Caballero B, Vega-Naredo I, Sierra V et al. Favorable effects of prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescence-accelerated mice. J Pineal Res 2008 45 : 302 311.
29. Rosales-Corral S, Tan DX, Reiter RJ et al. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-β peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J Pineal Res 2003 35 : 80 84. (Pubitemid 36960345)
30. Mayo JC, Sainz RM, Tan DX et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005 165 : 139 149. (Pubitemid 40984631)
31. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004 18 : 537 539.
32. Pierpaoli W, Regelson W. Pineal control of aging: effect of melatonin and pineal grafting on aging mice. Proc Natl Acad Sci U S A 1994 91 : 787 791. (Pubitemid 24041487)
33. Sharman KG, Sharman EH, Yang E, Bondy SC. Dietary melatonin selectively reverses age-related changes in cortical cytokine mRNA levels, and their responses to an inflammatory stimulus. Neurobiol Aging 2002 23 : 633 638. (Pubitemid 34495466)
34. Sharman EH, Vaziri ND, Ni Z, Sharman KG, Bondy SC. Reversal of biochemical and behavioral parameters of brain aging by melatonin and acetyl L-carnitine. Brain Res 2002 957 : 223 230. (Pubitemid 35356517)
35. Resuehr D, Olcese J. Caloric restriction and melatonin substitution: effects on murine circadian parameters. Brain Res 2005 1048 : 146 152. (Pubitemid 40800269)
36. Ebihara S, Marks T, Hudson DJ, Menaker M. Genetic control of melatonin synthesis in the pineal gland of the mouse. Science 1986 231 : 491 493. (Pubitemid 16163738)
37. Roseboom PH, Namboodiri MA, Zimonjic DB et al. Natural melatonin 'knockdown' in C57BL/6J mice: rare mechanism truncates serotonin N-acetyltransferase. Brain Res Mol Brain Res 1998 63 : 189 197. (Pubitemid 28559101)
38. Olcese J, Sikes HE, Resuehr D. Induction of PER1 mRNA expression in immortalized gonadotropes by gonadotropin-releasing hormone (GnRH): involvement of protein kinase C and MAP kinase signaling. Chronobiol Int 2006 23 : 143 150. (Pubitemid 43739026)
39. Pappolla MA, Chyan YJ, Omar RA et al. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998 152 : 871 877. (Pubitemid 28173347)
40. Praticò D, Uryu K, Leight S, Trojanowski JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001 21 : 4183 4187. (Pubitemid 32538543)
41. Honda K, Smith MA, Zhu X et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005 280 : 20978 20986. (Pubitemid 40805655)
42. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008 45 : 235 246.
43. Kotler M, Rodríguez C, Sáinz RM, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998 24 : 83 89. (Pubitemid 28168319)
44. Mayo JC, Sainz RM, Antolin I. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 2002 59 : 1706 1713. (Pubitemid 35346974)
45. Subramanian P, Mirunalini S, Pandi-Perumal SR, Trakht I, Cardinali DP. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur J Pharmacol 2007 571 : 116 119. (Pubitemid 47385902)
46. Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 2005 1037 : 209 213. (Pubitemid 40362399)
47. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009 15 : 43 50.
48. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006 27 : 41 49.
49. Rojo LE, Fernández JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008 39 : 1 16. (Pubitemid 350192021)
50. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002 35 : 419 432. (Pubitemid 34879943)
51. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006 3 : 27.
52. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullen MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005 2 : 9.
53. Yamamoto M, Kiyota T, Horiba M et al. Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007 170 : 680 692. (Pubitemid 47339404)
54. Townsend KP, Praticò D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005 19 : 1592 1601. (Pubitemid 41429517)
55. Rodríguez MI, Escames G, López LC et al. Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence- accelerated mice. J Pineal Res 2007 42 : 272 279. (Pubitemid 46365065)
56. Yan SD, Chen X, Fu J et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996 382 : 685 691. (Pubitemid 26282167)
57. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997 23 : 134 147. (Pubitemid 27217017)
58. Pappolla MA, Sos M, Omar RA et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997 17 : 1683 1690. (Pubitemid 27089813)
59. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid β-protein (Aβ) in human neuroblastoma cells. Biochemistry 2000 39 : 6951 6959. (Pubitemid 30390389)
60. Goldsbury C, Whiteman IT, Jeong EV, Lim YA. Oxidative stress increases levels of endogenous amyloid-β peptides secreted from primary chick brain neurons. Aging Cell 2008 7 : 771 775.
61. Pappolla MA, Bryant-Thomas TR, Herbert D et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003 61 : 199 205. (Pubitemid 36875301)
62. Tan DX, Manchester LL, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42. (Pubitemid 44924323)
63. Masilamoni JG, Jesudason EP, Dhandayuthapani S et al. The neuroprotective role of melatonin against amyloid β peptide injected mice. Free Radic Res 2008 42 : 661 673.
64. Pappolla MA, Simovich MJ, Bryant-Thomas TT et al. The neuroprotective activities of melatonin against the Alzheimer β-protein are not mediated by melatonin membrane receptors. J Pineal Res 2002 32 : 135 142. (Pubitemid 34309879)
65. Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 2008 154 : 1182 1195. (Pubitemid 351992057)